An observational study in Williams Syndrome and Autism Disorder, sponsored by Qilu Hospital of Shandong University. Not yet recruiting at 1 site in China. Open to participants aged 3 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Qilu Hospital of Shandong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Williams Syndrome (WS) is a rare neurodevelopmental disorder, usually caused by microdeletions of approximately 26 genes in the long arm (7q11.23) region of chromosome 7. Children with this syndrome often exhibit distinctive facial features, mild to moderate intellectual disability, impaired spatial cognition, pronounced social extraversion, and relatively reserved language-expression characteristics. Although individuals with WS often demonstrate strong social interest and prosocial behaviors, significant deficiencies in abstract thinking, executive function, and visuospatial ability are frequently observed. At present, treatment for WS mainly focuses on behavioral intervention and educational rehabilitation, and clear molecular or pharmacological treatment methods remain limited. Due to the "opposite but related" social-cognitive profile observed in comparison with autism spectrum disorder, in-depth exploration of neural and molecular mechanisms underlying these differences has substantial scientific significance for understanding the biological basis of social-cognitive impairment.
29 studies on the registry are indexed under Williams Syndrome; 11 are open to participants now.
This study's planned enrollment of 75 is below the median of 100 across 15 observational studies indexed under Williams Syndrome.
Browse Williams Syndrome studies →Qilu Hospital of Shandong University is the lead sponsor of 311 studies on the registry; 188 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Source of research participants: WS research participants, ASD research participants and normal children controls who visited the pediatric health rehabilitation clinic
Participants for Williams Syndrome Study
Inclusion criteria must all be met:
Participants for Autism Spectrum Disorder Study
Inclusion criteria must all be met:
Participants for Healthy Children Study
Inclusion criteria must all be met:
Common Exclusion Criteria for All Study Participants
Any of the following conditions must be met to be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After clinical diagnosis and confirmation through fluorescence in situ hybridization (FISH) testing, a typical microdeletion of approximately 1.55 Mb in the chromosome 7q11.23 region was identified.
It meets the clinical diagnostic criteria of the Second Edition of the Autism Diagnostic Observation Scale (ADOS-2).
There is no history of neurodevelopmental disorders, mental illness or major neurological diseases
The score of Motor Quotient in Peabody Developmental Motor Scales, Second Edition (PDMS-2)
Motor development will be assessed using the Peabody Developmental Motor Scales, Second Edition (PDMS-2). The endpoint is the Motor Quotient (range: 50-150). Higher scores indicate better motor functioning (i.e., better outcome). Group differences will be evaluated across WS, ASD, and typically developing controls.
Time frame: Baseline
The score of Developmental Quotient (DQ) in Gesell Developmental Schedules (GDS)
Neurodevelopmental level will be assessed using the Gesell Developmental Schedules (Gesell Developmental Scale). The endpoint is the Developmental Quotient (DQ) (range: 0-130). Higher scores indicate better developmental functioning (i.e., better outcome). Group differences will be evaluated across WS, ASD, and typically developing controls.
Time frame: Baseline
Fractional Anisotropy (FA)
White matter microstructural integrity will be quantified using DTI-derived fractional anisotropy (FA). FA values range from 0 to 1, with higher values indicating greater directional diffusion and typically better white matter integrity (i.e., better outcome). Group differences will be evaluated across WS, ASD, and typically developing controls. Unit of Measure : mm²/s (typically reported as ×10-³ mm²/s)
Time frame: baseline
The score pf Social Responsiveness Scale, Second Edition (SRS-2)
Social communication will be assessed using the Social Responsiveness Scale, Second Edition (SRS-2). The primary endpoint is the SCI T-score (range: 0-100). Higher scores indicate worse social communication impairment (i.e., poorer outcome). Group differences will be compared across WS, ASD, and typically developing controls.
Time frame: baseline
Diffusion Tensor Imaging (DTI) Axial Diffusivity (AD)
White matter microstructural properties will be quantified using DTI-derived axial diffusivity (AD). AD will be summarized as the mean AD within prespecified white matter regions of interest (ROIs) (or whole-brain white matter skeleton, if applicable). Higher AD indicates greater diffusion along the principal axis; interpretation (better/worse) is direction-dependent and will be interpreted in the context of neurodevelopmental findings. Unit of Measure: mm²/s (typically reported as ×10-³ mm²/s)
Time frame: Baseline
Diffusion Tensor Imaging (DTI) Mean Diffusivity (MD)
DTI-derived mean diffusivity (MD) will be calculated and summarized as the mean MD within prespecified white matter ROIs (or whole-brain white matter skeleton, if applicable). Higher MD indicates greater overall water diffusion and is commonly interpreted as reduced microstructural integrity (worse outcome). Unit of Measure: mm²/s (typically reported as ×10-³ mm²/s)
Time frame: Baseline
Diffusion Tensor Imaging (DTI) Radial Diffusivity (RD)
DTI-derived radial diffusivity (RD) will be calculated and summarized as the mean RD within prespecified white matter ROIs (or whole-brain white matter skeleton, if applicable). Higher RD indicates greater diffusion perpendicular to the principal axis and is often interpreted as poorer myelination or reduced microstructural integrity (worse outcome).Unit of Measure: mm²/s (typically reported as ×10-³ mm²/s)
Time frame: Baseline
Structural MRI (sMRI) Cortical Volume
Cortical morphology will be quantified from T1-weighted structural MRI. Cortical volume will be computed using an automated cortical reconstruction pipeline (e.g., FreeSurfer) and summarized as mean cortical volume (mm³) within prespecified cortical ROIs (or total cortical gray matter volume, if applicable). Higher cortical volume indicates greater cortical tissue volume. Unit of Measure: mm³
Time frame: Baseline
Structural MRI (sMRI) Cortical Thickness
Cortical morphology will be quantified from T1-weighted structural MRI. Cortical thickness will be computed and summarized as mean cortical thickness (mm) within prespecified cortical ROIs (or mean global cortical thickness, if applicable). Higher thickness indicates greater cortical thickness;Unit of Measure: mm
Time frame: Baseline
Structural MRI (sMRI) Subcortical Structure Volume
Subcortical anatomy will be quantified from T1-weighted structural MRI. Subcortical structure volumes (e.g., amygdala, hippocampus, thalamus, caudate, putamen, pallidum) will be computed using an automated segmentation pipeline (e.g., FreeSurfer) and summarized as volume (mm³) for prespecified subcortical regions. Higher volume indicates greater structure volume; Unit of Measure: mm³
Time frame: Baseline
Plan to share: Yes
Supporting information: Study protocol
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qilu Hospital of Shandong University →